Abstract
Gossypol, a polyphenolic compound which depletes cellular energy by inhibition of several intracellular dehydrogenases, has been shown to have antiproliferative activity against human glial tumor cell lines in vitro and in nude mouse xenografts. Human trials of gossypol as a male contraceptive have demonstrated safety of long-term administration. We studied the activity of Gossypol 10 mg PO bid in 27 patients with pathologically confirmed glial tumors which had recurred after radiation therapy. Fifteen patients had glioblastoma, 11 patients anaplastic astrocytoma, 1 patient relapsed low grade glioma. Response was assessed every 8 weeks using CT/MRI scan and clinical criteria including decadron requirement. Treatment was continued until disease progression. Two patients had partial response (PR); 4 had stable disease for 8 weeks or more. One patient maintained a PR with improved KPS for 78 weeks. The other had a PR lasting 8 weeks. Toxicity was mild: 2 heavily pretreated patients had mild thrombocytopenia, 5 patients developed hypokalemia, 3 patients developed grade 2 hepatic toxicity and peripheral edema. Gossypol levels measured by HPLC did not correlate with response or toxicity in this study.
We conclude that gossypol is well tolerated and has a low, but measurable, response rate in a heavily pretreated, poor-prognosis group of patients with recurrent glioma. The presumed novel mechanism of action, lack of significant myelosuppression, and activity in patients with advance glioma support further study of gossypol as an antineoplastic agent.
Similar content being viewed by others
References
Fine H, Dear K, Loeffler J, Black P, Canellos G: Metaanalysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71: 2585–2597, 1993
Oude Weernink PA, Rijksen G, Staal GE: Phosphorylation of pyruvate kinase and glycolytic metabolism in three human glioma cell lines. Tumour Biol 12(6): 339–52, 1991
Stefanini M: Enzymes, Isozymes and enzyme variants in the diagnosis of cancer. Cancer 55: 1931–1936, 1985
Timperley W: Lactate dehydrogenase isozymes in tumors of the nervous system. Acta Neuropathol (Berl) 19: 20–24, 1974
Gerhardt W, Clausen J, Christensen E, Riishede J: Lactate dehydrogenase isoenzymes in the diagnosis of human benign and malignant brain tumors. J Nat Canc Inst 38(3): 343–57, 1967
Haglid K, Carlsson CA, Thulin CA: Lactate dehydrogenase isoenzymes and proteins in human gliomas. Neurochirurgia 13(1): 19–28, 1970
Egami H, Takeshita I, Fukui M, Kitamura K: Supernumerary lactate dehydrogenase isozymes in human gliomas. J Neurolog Sci 61(1): 1–12, 1983
Keniry MA, Hollander C, Benz CC: The effect of gossypol and 6-aminonicotinamide on tumor cell metabolism: a 31Pmagnetic resonance spectroscopic study. Biochem Biophys Res Com 164(2): 947–53, 1989
Qian SZ, Wang ZG: Gossypol: a potential antifertility agent for males. (Review). Ann Rev Pharm Toxicol 24: 329– 60, 1984
Benz C, Hollander C, Keniry M, James TL, Mitchell M: Lactic dehydrogenase isozymes, 31P magnetic resonance spectroscopy, and in vitro antimitochondrial tumor toxicity with gossypol and rhodamine-123. J Clin Invest 79(2): 517–23, 1987
Tso WW, Lee CS: Lactate dehydrogenase-X: an isozyme particularly sensitive to gossypol inhibition. Internat J Androl 5(2): 205–9, 1982
Teng CS: Gossypol-induced apoptotic DNA fragmentation correlates with inhibited protein kinase C activity in spermatocytes. Contraception 52(6): 389–95, 1995
Ligueros M, Jeoung D, Tang B, Hochhauser D, Reidenberg M, Sonenberg M: Gossypol inhibition of mitosis, cyclin D1 and Rb protein in human mammary cancer cells and cyclin-D1 transfected human fibrosarcoma cells. Brit J Canc 76(1): 21–8, 1997
Shidaifat F, Canatan H, Kulp S, Sugimoto Y, Zhang Y, Brueggemeier R, Somers W, WY. C, Wang H, Lin Y: Gossypol arrests human benign prostatic hyperplastic cell growth at G0/G1 phase of the cell cycle. Anticancer Res 17(2A): 1003–9, 1997
Seghal A: Molecular changes during the genesis of brain tumors. Sem Surg Onc 14(1): 3–12, 1998
Ford JM, Hait WN, Matlin SA, Benz CC: Modulation of resistance to alkylating agents in cancer cell by gossypol enantiomers. Cancer Letters 56(1): 85–94, 1991
Coyle T, Levante S, Shetler M, Winfield J: In vitro and in vivo cytotoxicity of gossypol against central nervous system tumor cell lines. J Neuro-oncol 19(1): 25–35, 1994
Wu DF, Yu YW, Tang ZM, Wang MZ: Pharmacokinetics of (C=+)-, (C)-, and (+)-gossypol in humans and dogs. Clin Pharm Therapeut 39(6): 613–8, 1986
Flack MR, Pyle RG, Mullen NM, Lorenzo B, Wu YW, Knazek RA, Nisula BC, Reidenberg MM: Oral gossypol in the treatment of metastatic adrenal cancer. J Clin Endocrinol Metabol 76(4): 1019–24, 1993
Han ML, Wang YF, Tang MY, Ge QS, Zhou LF, Zhu PD, Sun YT: Gossypol in the treatment of endometriosis and uterine myoma. Contribut Gyn Obstet 16: 268–70, 1987
Stein RC, Joseph AE, Matlin SA, Cunningham DC, Ford HT, Coombes RC: A preliminary clinical study of gossypol in advanced human cancer. Cancer Chemother Pharmacol 30(6): 480–2, 1992
Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E, Carbone P: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6): 649–655, 1982
Coyle T, Baptista J, Winfield J, Clark K, Poiesz B, Kirshner J, Scalzo S, Newman-Palmer N, King R, Graziano S: Mechlorethamine, Vincristine, and Procarbazine chemotherapy for recurrent high-grade glioma in adults: a phase II study. J Clin Oncol 8: 2014–2018, 1990
Stumpf WE, Sar M, Haider SG, Xue SP, Chen KQ: Sites of action of gossypol studied by autoradiography and enzyme histochemistry. Contraception 37(3): 257–67, 1988
Strom-Hansen T, Cornett C, Jaroszewski JW: Interaction of gossypol with amino acids and peptides as a model of enzyme inhibition. Internat J Pept Prot Res 34(4): 306–10, 1989
Liang XS, Rogers AJ, Webber CL, Ormsby TJ, Tiritan ME, Matlin SA, Benz CC: Developing gossypol derivatives with enhanced antitumor activity. Invest New Drugs 13(3): 181–6, 1995
Reidenberg MM, Gu Z-P, Lorenzo BJ et al.: Differences in serum potassium concentrations in normal men in different geographic locations. Clin Chem 39: 72–5, 1993
Gu Z-P, Segal S, Reidenberg MM: Serum potassium values in normal men in Shanghai compared with men from Shanghai living abroad. Clin Chem 40: 340, 1994
Zhou LF, Lei HP: (Effect of gossypol acetic acid on the uterus and ovary) (Chinese). Yao Hsueh Hsueh Pao – Act Pharm Sin 19(3): 220–3, 1984
Brada M, Sharpe G: Chemotherapy of high-grade gliomas: beginning of a new era or the end of the old? Eur J Canc 32A(13): 2193–4, 1996
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bushunow, P., Reidenberg, M.M., Wasenko, J. et al. Gossypol Treatment of Recurrent Adult Malignant Gliomas. J Neurooncol 43, 79–86 (1999). https://doi.org/10.1023/A:1006267902186
Issue Date:
DOI: https://doi.org/10.1023/A:1006267902186